← Research library
DexCom
- Rating
- Price at publication
- $65.68
- Target price
- $87.07
- Stated upside
- +32.6%
- Published
- 26 March 2026
Thesis
G7 15-day, Stelo's over-the-counter expansion and Type 2 coverage wins position DexCom as the premium CGM franchise in a secular growth market.
Key risks
- 01Pricing competition from Abbott’s Libre
- 02GLP-1 drugs could reduce the need for glucose monitors
- 03A history of FDA warning letters
Price, target and upside are as stated in the report on 26 March 2026, not updated since.
Full report
Open in a new tab ↗Educational research. This report reflects the views of its student author as of 26 March 2026. It is not investment advice or a recommendation to buy or sell any security. Full disclaimer.